Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to Associate Professor Francesca Buffa who has been awarded a five-year €2M grant by the European Research Council (ERC) to develop computer simulations of cancer cell behaviour, to help us personalise cancer treatment and prevent drug resistance.

In many cases we know which parts of cells go wrong when they divide uncontrollably, leading to cancer. Also, we are becoming better and better at developing drugs which correct each individual problem.

However, cancer cells often depend on more than one thing going wrong (often a gene mutation). This series of changes “rewires” the cancer cell circuitry, and each person’s cancer will have its own combination of re-wiring.  This means that each person will need a different drug or combination of drugs to correct this rewiring and cure their disease.

When tumours no longer respond to drug treatment in the clinic, they have often become resistant by gaining more mutations and switching their circuitry. Then it is difficult for us to know which treatment to give.

To help us understand the flexibility in cancer cell circuitry, Francesca (a mathematical biologist) is constructing ‘virtual’ cancer cells inside a computer from what we know about the mutations that affect real cancer cell behaviour. Effectively, she is turning the cancer cell ‘circuits’ into real electrical circuits inside a computer.

These “in-silico“ cancer cells undergo constant improvements using up-to-date information from cancer cell biologists, until hopefully the cancer cells inside the computer will behave just like real living cancer cells.

The virtual cancer cells will enable us to test the effects of different drugs or drug combinations in a computer rather than in real-world clinical trials. This will dramatically increase the speed and reduce the cost of research.

Eventually, a biopsy from each real tumour could be used to generate an equivalent virtual tumour, which would then be used to quickly identify the best therapy for that patient. This means that Francesca’s work represents a potentially important step towards truly personalised cancer medicine.

Similar stories

Multi-cancer blood test shows real promise in NHS trial

An NHS trial of a new blood test for more than 50 types of cancer correctly revealed two out of every three cancers in more than 5,000 people who had visited their GP with suspected symptoms, in England or Wales. The test also correctly identified the original site of cancer in 85% of those cases.

The Howat Foundation to fund Chair in Clinical Oncology

Oxford Cancer announce the endowment of a Chair in Clinical Oncology, thanks to generous philanthropic support from The Howat Foundation

New Oxford and Nottingham developed tool uses existing health records to predict people’s risk of developing lung cancer within the next 10 years

A team of researchers from the University of Oxford and the University of Nottingham have developed a new tool, called ‘CanPredict’, aimed at identifying the people most at risk of developing lung cancer over the next 10 years, and put them forward for screening tests earlier, saving time, money and, most importantly, lives.

Scientists find genetic ‘marker’ linked to serious side-effects from skin cancer treatment

New research from the Fairfax Group has identified a genetic marker that could be used to predict a patient’s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the city’s two National Institute for Health and Care Research (NIHR) Biomedical Research Centres (BRC).

The Department represented at the European Radiation Research Society annual conference

Researchers from the Department of Oncology attend the prestigious European Radiation Research Society (ERRS) in annual conference in Catania, Italy to present their research in Radiation Oncology.